Purchase this article with an account.
Yuji Oshima, Miho Yasuda, Kumiko Kano, Ayako Yoshida, Hitomi Asato, Shintaro Nakao, Shigeo Yoshida, Tatsuro Ishibashi; Predictive Factors of Visual Acuity Deterioration after Ranibizumab Treatment for Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2917.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the predictive factors of visual acuity deterioration one year after intravitreal injections of ranibizumab (IVR) for age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) in Japanese patients.
One hundred fifty two eyes undergoing IVR treatment (AMD 84 eyes; PCV 68 eyes) were retrospectively studied. Best-corrected visual acuity (BCVA) change of 0.3 or more in log MAR VA was considered significant. Worsening in BCVA was defined as a decrease of > 0.3 log MAR units. The BCVA outcomes at one year after treatment were analyzed based on the following: age, sex, VA, greatest linear dimension, past treatment, FA classification, central retinal thickness, retinal bleeding, retinal pigment epithelium detachment (PED), hypertension, diabetes, and smoking habits.
Log MAR VA decreased by 0.3 or more in 21 eyes (13.8%) (AMD 12 eyes; PCV 9 eyes). Multivariate logistic regression analysis found the independent predictor for VA deterioration to be serous PED (odds ratio [OR], 3.93; 95% confidence interval [CI], 1.35 to 14.3) and the absence of classic choroidal neovascularization (CNV) (OR, 4.25; 95%CI, 1.65 to 10.8).
IVR is well tolerated in eyes of Japanese patients with AMD and PCV. PED and the absence of classic CNV at baseline may be risk factors for VA deterioration.
This PDF is available to Subscribers Only